Microtiter Plate Assay for Mutant Ligand-GPCR Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the binding ability of G-protein coupled receptors (GPCRs) to ligands are costly and limited in scope, making it difficult to identify stable mutant GPCR-ligand pairs for drug discovery and biochemical processes.
Innovation Solution
A method using a microtiter plate with GPCRs and mutants of ligands is employed, where the binding ability of mutants is assessed by comparing their interaction with the parent ligand, allowing for the identification of mutants with stronger or weaker binding affinities, and optimizing these pairs for drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for determining GPCR-ligand binding ability are used, then binding assessment can be performed, but the cost is high and the scope is limited
Solution Approach 1:
The microtiter plate assay platform is designed to universally assess binding ability across multiple GPCR-ligand pairs simultaneously. The method can evaluate parent ligands, mutant ligands, and their combinations in a single experimental setup, making the measurement system multi-functional and broadly applicable to various GPCR families and ligand types.
Solution Approach 2:
The invention combines multiple binding assessments into a single integrated microtiter plate experiment. By co-expressing multiple GPCRs and testing multiple ligands in the same plate, the method merges what would traditionally require separate experiments, thereby expanding scope while maintaining measurement precision.
2Measurement precision
If multiple mutant ligands are screened individually, then binding affinity can be determined, but the process is costly and time-consuming
Solution Approach 1:
The method merges the screening of multiple mutant ligands into a single microtiter plate experiment. By co-expressing multiple GPCRs and testing multiple ligands simultaneously, the system achieves high-throughput screening without sacrificing binding affinity determination accuracy, thereby dramatically improving productivity.
Solution Approach 2:
The assay uses excess ligand conditions to ensure saturation binding, which simplifies the analysis and allows rapid comparison of binding affinities across multiple mutants. This excessive action approach enables quick screening of many ligands without requiring complex kinetic measurements for each individual mutant.
3Stability of the object's composition
If GPCRs are mutated to improve binding stability, then drug discovery potential increases, but the complexity of identifying stable pairs increases
Solution Approach 1:
The method segments the identification process by first screening mutant ligands individually against multiple GPCRs to identify promising pairs, then focusing detailed stability optimization only on those specific pairs. This segmentation reduces the overall complexity by breaking down the problem into manageable stages rather than attempting to optimize all possible pairs simultaneously.
Solution Approach 2:
The invention systematically varies parameters such as ligand concentration, incubation time, and temperature to identify conditions that maximize binding stability for mutant pairs. By changing these parameters in a controlled manner, the method simplifies the identification process while achieving stable GPCR-ligand pairs with high drug discovery potential.
Data Source
AI summary
Method of determining GPCR and mutateable ligand binding ability, includes providing a well microtiter plate with well array having rows and columns, GPCR or rhodopsin in wells, and parent ligand mutant binding to GPCR when GPCR resides in conformation, contacting parent ligand mutants in wells with GPCR, coupling parent ligand to GPCR, and determining mutant ligand binding strength compared to standard parent ligand and GPCR by determining coupled mutant-GPCR complex in wells. Rhodopsin binding 403 mutants covering arrestin sequence provides functional 4th dimension arrestin crystal structures. Resulting single amino acid resolution functional maps reveal critical interactions in arrestin polar core and C-tail interrupted during activation. Amino acid patches reduce binding and act as direct binding rhodopsin interfaces. This and computational molecular docking active arrestin4 and light-activated rhodopsin develop arrestin-rhodopsin complex model. Combined mutants allow binding affinity modification and GPCR-ligand complex stability for diagnostics or intervention.